

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Pharmaron Beijing Co., Ltd.

康龍化成（北京）新藥技術股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 3759)

INSIDE INFORMATION

DISPOSAL OF A SHARES BY SUBSTANTIAL SHAREHOLDER

This announcement is made by Pharmaron Beijing Co., Ltd. (the **“Company”**) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the **“Listing Rules”**) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the **“SFO”**).

The Board was informed by Pharmaron Holdings Limited, a substantial shareholder of the Company (the **“Selling Shareholder”**), that it has disposed of an aggregate of 18,373,000 A shares of the Company (the **“A Shares”**), representing approximately 1.00% of the total issued share capital of the Company, by way of an inquiry-based transfer to specific institutional investors (the **“Disposal”**), subject to the applicable restrictions under the relevant laws of the People's Republic of China.

DISPOSAL OF A SHARES BY THE SELLING SHAREHOLDER

Details of the Disposal

The principal terms of the Disposal are as follows:

Number of A Shares disposed of:	18,373,000 A Shares, representing approximately 1.00% of the total issued share capital of the Company as at the date of this announcement.
Method of disposal:	By way of an inquiry-based transfer to specific institutional investors. The Disposal does not involve centralized bidding or block trading, and does not constitute a disposal through the secondary market.
Transfer price:	RMB38.89 per A Share
Transaction amount:	RMB714,525,970

Transferees: 13 institutional investors with corresponding pricing capability and risk tolerance, including (i) professional institutional investors meeting the offline investor conditions for ChiNext initial public offerings or other institutional investors as prescribed by the Shenzhen Stock Exchange, such as securities companies, fund management companies, futures companies, trust companies, wealth management companies, insurance companies, finance companies, qualified foreign institutional investors and private fund managers; and (ii) other private fund managers registered with the Asset Management Association of China whose participating products have completed the requisite filing.

Lock-up undertakings: Transferees shall not transfer the A Shares acquired under the Disposal within six months from the date of transfer.

EFFECT ON SHAREHOLDING OF THE SELLING SHAREHOLDER AND ITS CONCERT PARTIES

Immediately prior to the Disposal, the Selling Shareholder directly held 180,496,500 A Shares, representing approximately 9.82% of the total issued share capital of the Company as at the date of this announcement.

Immediately after the Disposal, the Selling Shareholder directly held 162,123,500 A Shares, representing approximately 8.82% of the total issued share capital of the Company as at the date of this announcement.

The Selling Shareholder is a concert party of Dr. LOU Boliang, Mr. LOU Xiaoqiang and Ms. ZHENG Bei, all being executive Directors and de facto controllers of the Company (collectively, the “**de facto controllers**”). On October 19, 2018, the de facto controllers entered into a voting rights agreement (which formalizes their pre-existing voting arrangement), pursuant to which they agreed to reach consensus on any proposal presented to the Board and the general meeting of shareholders of the Company for voting (the “**Voting Agreement**”). Pursuant to the Voting Agreement, the de facto controllers are concert parties and are deemed to be interested in each other’s interests in the Company under the SFO.

Immediately prior to the Disposal, the aggregate interests of the de facto controllers in the Company are 321,883,550 A Shares, representing 17.52% of the total issued share capital of the Company as at the date of this announcement.

Immediately after the Disposal, the aggregate interests of the de facto controllers in the Company will be 303,510,550 A Shares, representing 16.52% of the total issued share capital of the Company as at the date of this announcement.

The Company confirms that the Disposal does not result in any change of control of the Company and will not have any impact on the Company’s corporate structure and continuing operations.

Shareholders and potential investors should exercise caution when dealing in the securities of the Company.

By order of the Board
Pharmaron Beijing Co., Ltd.
康龍化成(北京)新藥技術股份有限公司
Dr. Lou Boliang
Chairman

Beijing, the PRC
October 15, 2026

As at the date of this announcement, the Board of Directors comprises Dr. LOU Boliang, Mr. LOU Xiaoqiang and Ms. ZHENG Bei as executive Directors; Mr. LI Shing Chung Gilbert as employee representative Director; Ms. WAN Xuan as non-executive Director; Ms. LI Lihua, Prof. TSANG King Fung and Ms. SHEN Rong as independent non-executive Directors.